openPR Logo
Press release

myriamed launches online shop

10-08-2021 12:29 PM CET | Health & Medicine

Press release from: myriamed GmbH

myriamed launches online shop

myriamed launches online shop

To deliver the best possible service to our customers, myriamed has launched its own online shop. The shop features various human iPSC derived cell types (myrCell) such as cardiomyocytes, skeletal muscle cells and stroma cells as well as various tissue types (myrTissue) such as cardiac tissue, fibrotic tissue or brain organoids. In addition, you can order our proprietary tissue culture plates (myrPlates) via the shop to cast and culture macroscale organoids.

Please visit the shop here:
http://bit.ly/myriamed_shop

About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and in the controlling of their fate as to the differentiation into defined cellular lineages and tissues (published for example in Tiburcy et al. 2017 and Long et al. 2018). The myriamed product portfolio is constantly evolving and based on a comprehensive IP portfolio to offer its know-how and associated services in drug development.
myriamed gives access to the following expertise:

• high quality human iPSC-derived somatic cells (myrCell) to be used in drug discovery and development.

• macroscale (3D) tissue (myrTissue) generated from the respective iPSC lines with properties of postnatal tissue for advanced screening and target validation.

• A highly parallelized phenotypic screening service (myrScreen).

myriamed has therefore two main types of activities, the generation of high-quality biological material allowing the research of new therapeutic targets, and the realization of customized phenotypic screenings.

To get in touch with us please visit:
http://bit.ly/myriamed_contact

myriamed GmbH
Rudolf-Wissell-Str. 28a
37079 Göttingen
Tel.: +49 551 28878-170
Email: info@myriamed.com
Web: www.myriamed.com

myriamed – the drug development accelerator

Separating the pharmacological wheat from the chaff is the primary goal of myriamed. Our proprietary human cell and engineered tissue models allow for the simulation of health and disease in the dish. Our platform technologies find broad applications in early stages of drug discovery and refinement of the most promising therapeutic candidates.
The availability of human cell and tissue models is transforming preclinical drug development. Applications range from early stages of lead discovery to advanced individualized phenotypic screens to shape a promising therapeutic candidate. myriamed offers a broad portfolio of highly standardized services as well as custom-made solutions to accelerate drug development.
At myriamed we focus on heart and skeletal muscle as well as on neuronal organoids. Our myrCell and myrTissue platforms define wanted and unwanted drug effects in a unique human context. myrScreen combines our expertise in phenotypic drug screens and enables deep phenotyping of drug effects on healthy or diseased human heart and skeletal muscle as well as on neuronal organoids.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release myriamed launches online shop here

News-ID: 2422397 • Views: 299

More Releases from myriamed GmbH

myriamed is a member of the international 4D Bioprinting network
myriamed has become a member of the ZIM innovation network 4D Bioprinting. The network, which is led by EurA AG supports concrete innovative products and new services in the field of bioprinting for applications in biology, pharmacy, and medicine. Thus, the network promotes the commercialization of the innovative technologies of the network partners by market-oriented R&D projects and establishment of new value chains for biopharmaceuticals and medicine. Phase 1 of the
myriamed has joined Science Exchange
Science Exchange, the leading SaaS-enabled marketplace platform for outsourced R&D services, has partnered with myriamed. Visit myriamed’s profile to inquire about our services or request a quote. There are no additional contracts required if you request on Science Exchange and you can order immediately. Please visit our profile here: http://bit.ly/myriamed_Science_Exchange About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and
myriamed is now a member of the Network for Pharma Solutions
We are proud to announce that myriamed is now a member of the Network for Pharma Solutions (NetPhaSol). NetPhaSol is a cooperation network focusing on drug discovery & development. It serves as a platform for research, development and marketing of new products, technologies and services in drug development. About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and in
Helping to accelerate the development of novel drugs against Covid-19 disease
Even though vaccines against Covid-19 will be available soon, artificial herd immunity via vaccination will probably not reached until the end of 2021. Thus, the current fight against Covid-19 disease heavily relies on already available drugs. Unfortunately, there is hardly any drug that fights the disease effectively. Cortisone based therapeutics are currently the ones used most frequently and most successfully. The originally promising drug Remdesivir, which has been approved for the

All 5 Releases


More Releases for Tiburcy

myriamed has joined Science Exchange
Science Exchange, the leading SaaS-enabled marketplace platform for outsourced R&D services, has partnered with myriamed. Visit myriamed’s profile to inquire about our services or request a quote. There are no additional contracts required if you request on Science Exchange and you can order immediately. Please visit our profile here: http://bit.ly/myriamed_Science_Exchange About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and
myriamed is now a member of the Network for Pharma Solutions
We are proud to announce that myriamed is now a member of the Network for Pharma Solutions (NetPhaSol). NetPhaSol is a cooperation network focusing on drug discovery & development. It serves as a platform for research, development and marketing of new products, technologies and services in drug development. About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and in
Helping to accelerate the development of novel drugs against Covid-19 disease
Even though vaccines against Covid-19 will be available soon, artificial herd immunity via vaccination will probably not reached until the end of 2021. Thus, the current fight against Covid-19 disease heavily relies on already available drugs. Unfortunately, there is hardly any drug that fights the disease effectively. Cortisone based therapeutics are currently the ones used most frequently and most successfully. The originally promising drug Remdesivir, which has been approved for the
myriamed’s myrPlates are now also available from ZAGENO
We are proud to announce that myriamed’s myrPlates are now also available in the ZAGENO life science, e-commerce marketplace. myrPlates can be used for the generation of engineered human tissues. By parallel culture of up to 48 tissues in one myrPlate, e.g. contractile heart muscles or skeletal muscles can be obtained to serve numerous applications, such as drug screening and disease modelling. About myriamed: myriamed has unique expertise in research and development
myriamed is now a member of Ksilink
We proudly announce that myriamed GmbH is now a member of the Ksilink association. The public private association is aiming to render drug development faster and more efficient, heading towards precision medicine. Together with its partners Ksilink develops and applies patient based disease models for phenotypic drug discovery purposes, and generates novel molecular entities for diseases with a high medical need, such as cardiac disorders. Ksilink is covering the entire
myriamed supports local soccer club
myriamed supports the local soccer club SV Puma with a small donation to help them buy new sportswear. We hope that the COVID-19 pandemic will be over soon and team sports can take place again. About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and in the controlling of their fate as to the differentiation into defined cellular lineages